B 244 - AOBiome

Drug Profile

B 244 - AOBiome

Alternative Names: B244; Nitrosomonas eutropha D23

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AOBiome
  • Class Antiacnes; Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Acne vulgaris
  • Phase II Atopic dermatitis; Hypertension; Rosacea
  • Phase I/II Allergic rhinitis
  • Phase I Eczema; Pruritus
  • Preclinical Skin disorders; Staphylococcal infections

Most Recent Events

  • 25 Oct 2017 Phase-I clinical trials in Eczema in USA (Topical) before October 2017 (AOBiome Therapeutic Pipeline, October 2017)
  • 25 Oct 2017 Phase-I clinical trials in Pruritus in USA (Topical) before October 2017 (AOBiome Therapeutic Pipeline, October 2017)
  • 19 Oct 2017 Adverse events and efficacy data from a phase IIb trial in Acne vulgaris released by AOBiome (NCT02832063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top